Announcement • May 24
Zhejiang Ruijiu Equity Investment Co., Ltd. acquired an additional 5% stake in Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) from Shenzhen Haiyuemen Biotechnology Development Co., Ltd., and Shenzhen Haide Xincheng Enterprise Management Partnership Enterprise (Limited Partnership) for approximately CNY 570 million.
Caitong Fund Management Co., Ltd., Xi'an Bocheng Fund Management Co., Ltd., Shenzhen Mutual Fund Management Co., Ltd., Nuode Asset Management Co., Ltd., GF Securities Co., Ltd. (SZSE:000776), Nanjing Shengquan Hengyuan Investment Co., Ltd., Huaan Securities Asset Management Co., Ltd., Shanghai Ningyuan Asset Management Co., Ltd., UBS Group AG (SWX:UBSG), Shanghai Ruiliang Private Fund Management Co., Ltd, Yuexinyao (Beijing) Private Fund Management Co., Ltd., Shenzhen Luchi Nanjiang Private Equity Investment Fund Management Co., Ltd., Shanghai Jinde Private Fund Management Co., Ltd., Guotai Haitong Securities Co., Ltd. (SHSE:601211), Shenzhen Changcheng Private Equity Fund Management Co., Ltd., Guolian Securities Asset Management Co., Ltd., J.P. Morgan Securities plc, Beijing Pingfan Private Equity Fund Management Co., Ltd., Jinxiu Zhonghe (Tianjin) Investment Management Co., Ltd., Qingdao Luxiu Investment Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Ningbo Meishan Bonded Port Lingding Investment Management Co., Ltd., Hunan Chengze Asset Management Co., Ltd, Tempo (Shanghai) Asset Management Company, Zhijian (Shaoxing Keqiao) Private Equity Fund Management Co., Ltd., Shanghai Yiyan Private Fund Management Co., Ltd., Xiamen Huahao Private Equity Fund Management Co., Ltd., Beijing Haoqing Private Equity Fund Management Co., Ltd., Yinwan Private Equity Fund Management (Hainan) Co., Ltd., Shenzhen Hongyuantaiping Asset Management Co., Ltd., Shanghai Muxin Private Fund Management Co., Ltd., Shanghai Jiupeng Asset Management Center (Limited Partnership), Shanghai Huijin Asset Management Co., Ltd., Shanghai Anfang Private Equity Fund Management Co., Ltd., Golden Eagle Asset Management Co. Ltd., Sealand Securities Co., Ltd. (SZSE:000750) and Zhejiang Ruijiu Equity Investment Co., Ltd. acquired an additional 5% stake in Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) from Shenzhen Haiyuemen Biotechnology Development Co., Ltd., Shenzhen Haide Ruibo Investment Co., Ltd., Shenzhen Haide Kangcheng Investment Partnership Enterprise (Limited Partnership) and Shenzhen Haide Xincheng Enterprise Management Partnership Enterprise (Limited Partnership) for approximately CNY 570 million on May 22, 2026. A cash consideration of CNY 25.68 per share will be paid. As part of consideration, CNY 568.57 million is paid towards common equity of Shenzhen Chipscreen Biosciences Co., Ltd.
Caitong Fund Management Co., Ltd., Xi'an Bocheng Fund Management Co., Ltd., Shenzhen Mutual Fund Management Co., Ltd., Nuode Asset Management Co., Ltd., GF Securities Co., Ltd. (SZSE:000776), Nanjing Shengquan Hengyuan Investment Co., Ltd., Huaan Securities Asset Management Co., Ltd., Shanghai Ningyuan Asset Management Co., Ltd., UBS Group AG (SWX:UBSG), Shanghai Ruiliang Private Fund Management Co., Ltd, Yuexinyao (Beijing) Private Fund Management Co., Ltd., Shenzhen Luchi Nanjiang Private Equity Investment Fund Management Co., Ltd., Shanghai Jinde Private Fund Management Co., Ltd., Guotai Haitong Securities Co., Ltd. (SHSE:601211), Shenzhen Changcheng Private Equity Fund Management Co., Ltd., Guolian Securities Asset Management Co., Ltd., J.P. Morgan Securities plc, Beijing Pingfan Private Equity Fund Management Co., Ltd., Jinxiu Zhonghe (Tianjin) Investment Management Co., Ltd., Qingdao Luxiu Investment Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Ningbo Meishan Bonded Port Lingding Investment Management Co., Ltd., Hunan Chengze Asset Management Co., Ltd, Tempo (Shanghai) Asset Management Company, Zhijian (Shaoxing Keqiao) Private Equity Fund Management Co., Ltd., Shanghai Yiyan Private Fund Management Co., Ltd., Xiamen Huahao Private Equity Fund Management Co., Ltd., Beijing Haoqing Private Equity Fund Management Co., Ltd., Yinwan Private Equity Fund Management (Hainan) Co., Ltd., Shenzhen Hongyuantaiping Asset Management Co., Ltd., Shanghai Muxin Private Fund Management Co., Ltd., Shanghai Jiupeng Asset Management Center (Limited Partnership), Shanghai Huijin Asset Management Co., Ltd., Shanghai Anfang Private Equity Fund Management Co., Ltd., Golden Eagle Asset Management Co. Ltd., Sealand Securities Co., Ltd. (SZSE:000750) and Zhejiang Ruijiu Equity Investment Co., Ltd. completed the acquisition of an additional 5% stake in Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) from Shenzhen Haiyuemen Biotechnology Development Co., Ltd., Shenzhen Haide Ruibo Investment Co., Ltd., Shenzhen Haide Kangcheng Investment Partnership Enterprise (Limited Partnership) and Shenzhen Haide Xincheng Enterprise Management Partnership Enterprise (Limited Partnership) for approximately CNY 570 million on May 22, 2026.
